Established in 1989, Proluo Pharmaceutical Co., Ltd. is a famous private enterprise, Hengdian Group pharmaceutical industry development platform and a listed company on the main board of the Shenzhen Stock Exchange.

After years of development, the company has good pharmaceutical R&D and manufacturing capabilities, and has raw material drug technology centers, CDMO R&D centers, and drug research institutes in Hengdian Headquarters, Shanghai, Boston and Hangzhou, USA respectively; in Dongyang Headquarters, Zhejiang, Weifang, Shandong , Anhui East Railway and Zhejiang Quzhou have built production bases, forming three main businesses: raw materials, CDMO, and preparations.

The company's raw materials business has accumulated a large amount of technical achievements and talent resources, and has taken the lead in China's raw materials industry and has continued to make a lot of investment in environmental protection governance, technological transformation, product research and development, etc. It has formed a strong competitive advantage in cost, quality, EHS and technology, and has become a leading domestic specialty raw materials enterprise.

As the core service provider of the CDMO business of the global innovative drug industry chain, Prolo Pharmaceutical has formed a long-term strategic cooperative relationship with top big pharma and biotech companies at home and abroad, and has accumulated a lot of business and maintained a rapid growth trend.

The preparation business adheres to differentiated and globalized strategies to achieve rapid development. Eight varieties have passed the new four categories of approval or consistency evaluation, creating the well-known domestic "Baishixin" and "Tianliwei" brands. Established the advantages of integrating raw material preparations and high technical barriers, the company's first high-end delayed release generic drug has been launched in the United States.

The company is in line with international standards and has established a high-standard quality management system and EHS management system to safeguard the healthy development of the enterprise. The company actively fulfills its social responsibilities, and the "three wastes" governance is at the forefront of the industry; it actively participates in social welfare activities such as paired poverty alleviation, accident rescue, and anti-epidemic donations, which have been widely praised by the society.

The company insists on driving high-quality development with scientific and technological innovation and continues to increase R&D investment. It has more than 1,000 R&D teams. It has established a R&D innovation system around the three major businesses, and has jointly built an innovation platform with universities to conduct chiral synthesis and continuous response. , biocatalysis, micro-pellet slow-controlled release and other sub-sectors have established certain advantages; at the same time, the company embraces intelligent manufacturing and vigorously promotes the construction of "continuity, automation, digitalization and intelligence" at the manufacturing end.

The company upholds the core values ​​of "common creation and common prosperity" and the core culture of "benevolence, mean, team, and execution", practices the mission of "technology creation, serving health", and implements "making raw materials, strengthening CDMO, and improving preparations ” development strategy, actively spread the corporate culture of “happy learning, happy exercise, happy work”.

Looking to the future, Pluo people are down-to-earth and full of passion, stride forward to achieve high-quality development of the company and the grand vision of "becoming a leading enterprise in China's science and technology pharmaceutical manufacturing."